Methods: hESC derived fibroblasts and osteoblasts were examined on different implant surfaces, which were modified by acid etching, blasting with soluble material and hydroxyapatite. Cytotoxic response of the differentiated hESC fibroblastic progenies were tested by PI staining and MTS assay. Osteogenesis performance was measured by bone-ALP and osteocalcin secretion and mineral deposit by differentiated osteoblasts.
Results: All the implant samples were not cytotoxic with hESC fibroblasts. The hESC fibroblasts attached well to the various implant samples. The hESC osteogenic differentiation and osteogenesis of hESC osteoblasts have shown positive results.
Conclusions: The study shows that hESC derived progenies are effective for assessing the cytotoxicity and osteogenesis of implants. We hope that with the success of this model, we will be able to conduct research and development for an optimal interface between bone and implants in a more cost-effective, humane and importantly, using unlimited, healthy and standardized cell lines of the actual host for safety and function testing of the implants.